{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:49:42Z","timestamp":1791888582292,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>A major priority in tuberculosis (TB) is to reduce effective treatment times and emergence of resistance. Recent studies in macrophages and zebrafish show that inhibition of mycobacterial efflux pumps with verapamil reduces the bacterial drug tolerance and may enhance drug efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Using mice, a mammalian model known to predict human treatment responses, and selecting conservative human bioequivalent doses, we tested verapamil as an adjunctive drug together with standard TB chemotherapy. As verapamil is a substrate for CYP3A4, which is induced by rifampin, we evaluated the pharmacokinetic\/pharmacodynamic relationships of verapamil and rifampin coadministration in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using doses that achieve human bioequivalent levels matched to those of standard verapamil, but lower than those of extended release verapamil, we evaluated the activity of verapamil added to standard chemotherapy in both C3HeB\/FeJ (which produce necrotic granulomas) and the wild-type background C3H\/HeJ mouse strains. Relapse rates were assessed after 16, 20, and 24 weeks of treatment in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>We determined that a dose adjustment of verapamil by 1.5-fold is required to compensate for concurrent use of rifampin during TB treatment. We found that standard TB chemotherapy plus verapamil accelerates bacterial clearance in C3HeB\/FeJ mice with near sterilization, and significantly lowers relapse rates in just 4 months of treatment when compared with mice receiving standard therapy alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data demonstrate treatment shortening by verapamil adjunctive therapy in mice, and strongly support further study of verapamil and other efflux pump inhibitors in human TB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201304-0650oc","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T15:48:17Z","timestamp":1372348097000},"page":"600-607","source":"Crossref","is-referenced-by-count":151,"title":["Acceleration of Tuberculosis Treatment by Adjunctive Therapy with Verapamil as an Efflux Inhibitor"],"prefix":"10.1093","volume":"188","author":[{"given":"Shashank","family":"Gupta","sequence":"first","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland"},{"name":"Howard Hughes Medical Institute, Chevy Chase, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak V.","family":"Almeida","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland"},{"name":"KwaZulu-Natal Research Institute for Tuberculosis and HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariama C.","family":"Maiga","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland"},{"name":"Howard Hughes Medical Institute, Chevy Chase, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Ammerman","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland"},{"name":"KwaZulu-Natal Research Institute for Tuberculosis and HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Bishai","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland"},{"name":"Howard Hughes Medical Institute, Chevy Chase, Maryland; and"},{"name":"KwaZulu-Natal Research Institute for Tuberculosis and HIV, Durban, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,9,1]]},"reference":[{"key":"2026032100463824600_bib1","author":"World Health Organization","year":"2011"},{"key":"2026032100463824600_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1462-5822.2009.01424.x","article-title":"Penitentiary or penthouse condo: the tuberculous granuloma from the microbe\u2019s point of view","volume":"12","author":"Paige","year":"2010","journal-title":"Cell Microbiol"},{"key":"2026032100463824600_bib3","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2165\/11317030-000000000-00000","article-title":"Efflux-mediated drug resistance in bacteria: an update","volume":"69","author":"Li","year":"2009","journal-title":"Drugs"},{"key":"2026032100463824600_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2011.02.022","article-title":"Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism","volume":"145","author":"Adams","year":"2011","journal-title":"Cell"},{"key":"2026032100463824600_bib5","article-title":"Inhibition of the Mycobacterium tuberculosis reserpine\u2013sensitive efflux pump augments intracellular concentrations of ciprofloxacin and enhances susceptibility of some clinical isolates","author":"Huang","journal-title":"J Formos Med Assoc"},{"key":"2026032100463824600_bib6","doi-asserted-by":"crossref","first-page":"e5305","DOI":"10.1371\/journal.pone.0005305","article-title":"Voltage gated calcium channels negatively regulate protective immunity to mycobacterium tuberculosis","volume":"4","author":"Gupta","year":"2009","journal-title":"PLoS One"},{"key":"2026032100463824600_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1574-6976.2005.00002.x","article-title":"Role of mycobacterial efflux transporters in drug resistance: an unresolved question","volume":"30","author":"De Rossi","year":"2006","journal-title":"FEMS Microbiol Rev"},{"key":"2026032100463824600_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/mdr.2009.0054","article-title":"Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs","volume":"16","author":"Gupta","year":"2010","journal-title":"Microb Drug Resist"},{"key":"2026032100463824600_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1164\/rccm.201011-1924OC","article-title":"Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux","volume":"184","author":"Louw","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032100463824600_bib10","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1073\/pnas.0505446102","article-title":"Ancestral antibiotic resistance in Mycobacterium tuberculosis","volume":"102","author":"Morris","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032100463824600_bib11","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1128\/AAC.46.9.2804-2810.2002","article-title":"Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis","volume":"46","author":"Viveiros","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100463824600_bib12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.19.2.382-402.2006","article-title":"Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria","volume":"19","author":"Piddock","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"2026032100463824600_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/591098","article-title":"Mycobacterium tuberculosis sigma factor E regulon modulates the host inflammatory response","volume":"198","author":"Fontan","year":"2008","journal-title":"J Infect Dis"},{"key":"2026032100463824600_bib14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.tim.2006.05.005","article-title":"Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm","volume":"14","author":"Nguyen","year":"2006","journal-title":"Trends Microbiol"},{"key":"2026032100463824600_bib15","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1128\/AAC.00550-09","article-title":"Role of the Mycobacterium tuberculosis p55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth","volume":"53","author":"Ramon-Garcia","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100463824600_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.chom.2007.09.006","article-title":"Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues","volume":"2","author":"Rohde","year":"2007","journal-title":"Cell Host Microbe"},{"key":"2026032100463824600_bib17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.20030846","article-title":"Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment","volume":"198","author":"Schnappinger","year":"2003","journal-title":"J Exp Med"},{"key":"2026032100463824600_bib18","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1128\/AAC.01756-09","article-title":"Human antimicrobial peptide LL-37 induces MefE\/Mel\u2013mediated macrolide resistance in Streptococcus pneumoniae","volume":"54","author":"Zahner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100463824600_bib19","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1128\/IAI.71.7.4112-4118.2003","article-title":"Toll-like receptor 4\u2013defective C3H\/HeJ mice are not more susceptible than other C3H substrains to infection with Mycobacterium tuberculosis","volume":"71","author":"Kamath","year":"2003","journal-title":"Infect Immun"},{"key":"2026032100463824600_bib20","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.jchromb.2010.09.032","article-title":"Determination of doxazosin and verapamil in human serum by fast LC-MS\/MS: application to document non-compliance of patients","volume":"878","author":"Chytil","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026032100463824600_bib21","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/00498254.2011.654001","article-title":"Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407","volume":"42","author":"Lee","year":"2012","journal-title":"Xenobiotica"},{"key":"2026032100463824600_bib22","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1073\/pnas.1203636109","article-title":"Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide","volume":"109","author":"Grosset","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026032100463824600_bib23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/AAC.40.3.552","article-title":"Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide","volume":"40","author":"Dhillon","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100463824600_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2125.1992.tb04091.x","article-title":"Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers","volume":"33","author":"John","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"2026032100463824600_bib25","first-page":"559","article-title":"Verapamil\u2013rifampin interaction","volume":"19","author":"Barbarash","year":"1985","journal-title":"Drug Intell Clin Pharm"},{"key":"2026032100463824600_bib26","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1378\/chest.94.5.954","article-title":"Near-total reduction in verapamil bioavailability by rifampin: electrocardiographic correlates","volume":"94","author":"Barbarash","year":"1988","journal-title":"Chest"},{"key":"2026032100463824600_bib27","doi-asserted-by":"crossref","first-page":"e30749","DOI":"10.1371\/journal.pone.0030749","article-title":"Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model","volume":"7","author":"Maiga","year":"2012","journal-title":"PLoS ONE"},{"key":"2026032100463824600_bib28","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1164\/ajrccm\/140.5.1189","article-title":"Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide","volume":"140","author":"Lecoeur","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"2026032100463824600_bib29","doi-asserted-by":"crossref","first-page":"e34538","DOI":"10.1371\/journal.pone.0034538","article-title":"Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis","volume":"7","author":"Machado","year":"2012","journal-title":"PLoS ONE"},{"key":"2026032100463824600_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0035-9203(89)90642-1","article-title":"Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil","volume":"83","author":"Neal","year":"1989","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2026032100463824600_bib31","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.3544220","article-title":"Reversal of chloroquine resistance in plasmodium falciparum by verapamil","volume":"235","author":"Martin","year":"1987","journal-title":"Science"},{"key":"2026032100463824600_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00609969","article-title":"The influence of antituberculosis drugs on the plasma level of verapamil","volume":"32","author":"Mooy","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"2026032100463824600_bib33","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1128\/AAC.00789-09","article-title":"Noninvasive pulmonary [18F]-2-fluoro-deoxy-d-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment","volume":"53","author":"Davis","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032100463824600_bib34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/infdis\/jir786","article-title":"Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions","volume":"205","author":"Harper","year":"2012","journal-title":"J Infect Dis"},{"key":"2026032100463824600_bib35","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1128\/AAC.00830-09","article-title":"Paradoxical effect of isoniazid on the activity of rifampin\u2013pyrazinamide combination in a mouse model of tuberculosis","volume":"53","author":"Almeida","year":"2009","journal-title":"Antimicrob Agents Chemother"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/188\/5\/600\/67239577\/ajrccm_188_5_600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/188\/5\/600\/67239577\/ajrccm_188_5_600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:49:09Z","timestamp":1774068549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/188\/5\/600\/8506791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,1]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,9,1]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201304-0650oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,9]]},"published":{"date-parts":[[2013,9,1]]}}}